Displaying 26 (all) recruiting clinical trials.
-
Phase 1b/2a Study of Gemcitabine and Nab-paclitaxel in Combination with VS-6766 and Defactinib in Patients with Previously Untreated Metastatic Adenocarcinoma of the Pancreas
This study is about testing a combination of drugs (gemcitabine, nab-paclitaxel, VS-6766, and defactinib) to treat a type of cancer called pancreatic ductal adenocarcinoma (PDAC ...
-
A dose escalation and expansion study of sonodynamic therapy with SONALA-001 in combination with Exablate 4000 Type-2 MR-guided focused ultrasound in patients with recurrent or progressive glioblastoma multiforme
This is a study testing a new non-invasive treatment called sonodynamic therapy (SDT) for recurrent or progressive glioblastoma (GBM). The study team will use intravenous ...
-
A Phase 1b/2 Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE)
This is a study that is divided into two phases: Phase 1b and Phase 2. The Phase 1b part will test different combinations of drugs ...
-
A Phase I/II Open-Label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics and Anti-Tumor Efficacy of DZD9008 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR or HER2 mutation
A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Efficacy of DZD9008 in Patients with Advanced Non-Small Cell Lung ...
-
A Modular Open-label Phase I/II Study to Evaluate the Safety Tolerability Pharmacokinetics and Efficacy of EP0031 in Patients with Advanced RET-altered Malignancies
RET alterations mostly happen in lung cancer and thyroid cancer, these alterations can be picked up on molecular testing and can be a target for ...
-
Phase 1/2 Multi-Center Open-Label Study to Evaluate the Safety Tolerability and Preliminary Anti-tumor Activity of TNG462 in Patients with MTAP-deleted Advanced or Metastatic Solid Tumors
A study called TNG462-C101 is being conducted to test a new medicine called TNG462 on patients with advanced or metastatic solid tumors who have a ...